Results 171 to 180 of about 1,612 (203)

Droxidopa in the Management of Hepatorenal Syndrome

Journal of Pharmacy Practice, 2022
Purpose Hepatorenal syndrome (HRS) is renal dysfunction associated with the hemodynamic consequences of advanced liver disease and cirrhosis. HRS is associated with a high mortality, and there remain high failure rates with first-line therapy aimed at improving perfusion. We report the use of droxidopa, an oral norepinephrine precursor, to aid in the
Andrea Bejjani, Youqi Zhang, Allison Behrens, Brian Murray, Neil Shah   +4 more
openaire   +2 more sources

Droxidopa for orthostatic hypotension

Journal of Hypertension, 2016
The systematic review and meta-analysis aims to determine the efficacy and safety of droxidopa in the treatment of orthostatic hypotension, following its recent approvals in the United States.MEDLINE, EMBASE, PubMed, Cochrane Controlled Trials Register, Web of Science, ProQuest, and the WHO Clinical Trials Registry were searched.
Victoria, Strassheim, Julia L, Newton, Maw Pin, Tan, James, Frith   +3 more
openaire   +2 more sources

Droxidopa for Symptomatic Neurogenic Hypotension

Cardiology in Review, 2017
Droxidopa is a first-in-class, orally available, synthetic amino acid precursor of norepinephrine that received accelerated Food and Drug Administration approval in February 2014 after Orphan Drug status for a debilitating condition known as symptomatic neurogenic orthostatic hypotension.
openaire   +2 more sources

Droxidopa for neurogenic orthostatic hypotension

Expert Opinion on Orphan Drugs, 2015
Introduction: Neurogenic orthostatic hypotension is a disabling manifestation of autonomic failure seen in disorders such as multiple system atrophy, pure autonomic failure, Lewy body disease, Parkinson’s disease, autonomic neuropathies and dopamine β-hydroxylase deficiency.Areas covered: Droxidopa is an orally administered norepinephrine prodrug that ...
openaire   +1 more source

Droxidopa in the Treatment of Postural Orthostatic Tachycardia Syndrome

American Journal of Therapeutics, 2017
Background: Postural orthostatic tachycardia syndrome (POTS) is a constellation of signs and symptoms that occur when a patient is upright and relieved by recumbence. Currently, no drugs are labeled for the treatment for POTS.
Mohammed, Ruzieh, Osama, Dasa, Ann, Pacenta, Beverly, Karabin, Blair, Grubb   +4 more
openaire   +2 more sources

Pilot Study of Droxidopa With Carbidopa in Adults With ADHD

Journal of Attention Disorders, 2015
Objective: We conducted a two-period (open-label and double-blind) pilot investigation of droxidopa, with and without carbidopa, for ADHD. Method: Twenty adult ADHD patients received open-label droxidopa titrated from 200 to 600 mg 3 times per day (TID; Weeks 1-3), then open-label droxidopa plus carbidopa titrated from 25 or 50 mg TID (Weeks 4-6).
Lenard A, Adler, Stephen W, Gorny
openaire   +2 more sources

Droxidopa approved for neurogenic orthostatic hypotension

American Journal of Health-System Pharmacy, 2014
Droxidopa, a synthetic amino acid precursor of norepinephrine, has been approved as oral therapy for the treatment of neurogenic orthostatic hypotension, FDA and Chelsea Therapeutics announced on February 18.
openaire   +1 more source

Droxidopa

Reactions Weekly, 2017
  +5 more sources